Product image of Idanuz (Icatibant) supplied by GNH India

Idanuz

Active Ingredient:
Icatibant
Origin:
EU

Idanuz (Icatibant)

Icatibant, the active ingredient in Idanuz, is a bradykinin B2 receptor antagonist presented as a sterile solution for subcutaneous injection use. It treats acute hereditary angioedema attacks in patients with type I or type II HAE. The drug is indicated for patients aged 12 years and older and is administered by a single subcutaneous injection at the onset of an attack.

GNH India supplies Idanuz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable sourcing, regulatory support and timely delivery across multiple regions.

Manufacturer / TM Owner

Norameda Uab

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Icatibant is used to treat hereditary angioedema (HAE) by rapidly counteracting bradykinin‑mediated swelling.
  • Hereditary angioedema type I: provides rapid reduction of swelling, pain and associated airway obstruction during acute attacks, improving patient comfort and safety.
  • Hereditary angioedema type II: delivers fast relief of edema and discomfort in attacks caused by dysfunctional C1‑inhibitor, helping to restore normal function.
  • Acute hereditary angioedema attacks in adults: shortens the duration of episodes, reduces severity, and facilitates quicker return to daily activities.

How It Works

  • Icatibant selectively binds to the bradykinin B2 receptor, preventing endogenous bradykinin from activating the receptor. By blocking this pathway, it inhibits bradykinin‑induced vasodilation and increased vascular permeability, thereby reducing the swelling and pain characteristic of hereditary angioedema attacks.

Side Effects

Icatibant may cause several adverse reactions, ranging from mild to serious.

Common Side Effects

  • Injection site pain or erythema
  • Local swelling or induration at the injection site
  • Nausea or mild gastrointestinal discomfort
  • Headache or dizziness
  • Transient flushing
  • Fatigue or malaise

Serious or Rare Side Effects

  • Anaphylactic or severe hypersensitivity reactions
  • Angioedema unrelated to HAE
  • Severe hypotension or shock
  • Thrombocytopenia or abnormal bleeding
  • Necrotic skin lesions at injection site
  • Acute respiratory distress

Precautions & Warnings

Before using Idanuz, consider the following safety measures.

  • Renal impairment: monitor renal function and adjust clinical observation as needed.
  • Hepatic disease: use with caution; assess liver enzymes regularly.
  • Pregnancy: limited clinical data; prescribe only if potential benefit outweighs risk.
  • Breastfeeding: unknown excretion in milk; evaluate risk versus benefit.
  • Concomitant ACE inhibitors or ARBs: may increase bradykinin levels; observe for enhanced edema.
  • Store at below 25°C: keep in original packaging, protect from moisture and direct sunlight.

Avoid Interactions

Icatibant can interact with other medicines that affect the bradykinin pathway or cardiovascular system.

Major Interactions (Avoid)

  • ACE inhibitors: additive bradykinin effect may worsen angioedema.
  • Angiotensin receptor blockers: potential increase in vascular permeability.
  • Nitrates: may potentiate vasodilatory response leading to hypotension.

Moderate Interactions (Monitor Closely)

  • Diuretics: monitor blood pressure and electrolytes.
  • Beta‑blockers: watch for exaggerated hypotensive episodes.
  • Other bradykinin antagonists: additive pharmacologic effect may increase risk of adverse events.

Frequently Asked Questions

Idanuz contains icatibant, a bradykinin B2 receptor antagonist indicated for the treatment of acute attacks of hereditary angioedema (HAE) in patients with type I or type II disease. It works by rapidly reducing swelling, pain, and airway obstruction associated with HAE episodes.

Icatibant selectively blocks the bradykinin B2 receptor, preventing bradykinin from triggering vasodilation and increased vascular permeability. By inhibiting this pathway, the drug limits the fluid leakage that causes the characteristic swelling of hereditary angioedema.

The dosage of Idanuz is determined by the prescribing healthcare professional based on the patient’s age, weight, and severity of the HAE attack. The prescriber will specify the exact amount and timing of each subcutaneous injection.

Safety data for icatibant in pregnancy and lactation are limited. It should be used only if the potential benefit justifies the possible risk to the fetus or infant, and the decision should be made by the treating physician.

To request Idanuz, submit an enquiry on the product page at gnhindia.com, indicating the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Idanuz (icatibant) is a selective bradykinin B2 receptor antagonist, whereas other approved options include C1‑esterase inhibitor concentrates and kallikrein inhibitors. Icatibant is administered subcutaneously as a single dose at attack onset, offering a rapid, targeted approach without the need for intravenous infusion.

Idanuz should be stored at temperatures below 25 °C, protected from moisture and direct sunlight. Keep the product in its original packaging until use, and avoid exposing it to extreme heat or freezing conditions.

Idanuz is supplied as a sterile solution for subcutaneous injection. The prescriber will instruct the patient or caregiver on the proper injection technique, typically delivering a single dose into the abdominal wall or thigh at the first sign of an HAE attack.

Serious adverse events include severe hypersensitivity reactions such as anaphylaxis, unexpected angioedema unrelated to HAE, and profound hypotension. Patients should be monitored for signs of these reactions, and immediate medical attention is required if they occur.

Idanuz is contraindicated in patients with known hypersensitivity to icatibant or any of the formulation components. Caution is also advised for individuals with severe renal or hepatic impairment, and it should not be used in patients where alternative approved therapies are more appropriate.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Icatibant

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT